Steven E. Hall Ph.D.

Background

Dr. Steven E. Hall, also known as Steve, Ph.D serves as the Chief Executive Officer at Esanex. Dr. Hall serves as a General Partner of Lilly Ventures. Previously, he was a Venture Partner at Lilly Ventures. He was a Co-Founder of Serenex, Inc. and served as the Senior Vice President of Research and Development, where he recruited and led a team in developing a novel discovery technology that advanced the target program from a novel screen to first patient dosed in just ... over three years. Dr. Hall served as the Vice President and Site Director at Sphinx Laboratories, Eli Lilly Research Laboratories, where he oversaw lead generation efforts in the areas of combinatorial chemistry, automation, high-throughput screening, biomolecular research, and information technology. He was a key member of a small team that developed and executed a strategy to partner Lilly’s expertise in high-throughput chemistry with three Japanese pharmaceutical companies with an aggregate value of more than $75 million. Dr. Hall served senior management positions in Medicinal Chemistry at Bristol-Myers Squibb. He started his career in 1982 as a Medicinal Chemist with the Squibb Institute for Medical Research and held positions of increasing responsibility for multiple projects in cardiovascular disease. He has been a Director of Nimbus Discovery, LLC since June 28, 2011. He serves as a Board Observer of Avid Radiopharmaceuticals and Viamet Pharmaceuticals. He serves as a Director of InnoCentive, Inc. He has been a Director of Lysosomal Therapeutics Inc since May 12, 2014 and Numerate, Inc. since June 24, 2014. He serves as a Director of FORMA Therapeutics Inc., Forma Therapeutics Holdings LLC and Hydra Biosciences Inc. He sits on the Boards of Esanex. He has been a Director of Cerulean Pharma Inc. since 2010. Dr. Hall is the Author of more than 40 papers and an Inventor on greater than 60 patents. Dr. Hall has more than 25 years of pharmaceutical experience from both multinational pharmaceutical companies and biotech organizations to the firm. He holds a Ph.D. in Organic Chemistry at the Massachusetts Institute of Technology and a B.S. in Chemistry from Central Michigan University.

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.